Herceptin (trastuzumab)

What gets paid for!? I remember having a HER2 3+ gastric cancer guy about 12 years ago. Got all better on Herceptin, but after 20 months there was progression. Couldn't get a second line therapy paid for. How do you do it? (Couldn't get free drug either). (@davideyoungmd)

#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)

But sir you will be astonished that in a country like Pakistan , people do not have access to Rituximab even in DLBCL...herceptin/Perjecta in Breast cancer,Others talking of polatuzuma,even for PFS benefits only....Do these patients have no rights to access to quality drugs? (@DrManzoorKhan1)

Patient with metastatic cholangiosarcoma with mRNA+ her2 (ihc, DNA NA) 24+ ongoing months PR on lapatinib/trastuzumab ⁦@AaronGoodman33⁩ ⁦⁦@BostonGenomics⁩ See Akram at al. JCO PO July 2023. Impressive response predicted by Her2 mRNA (@Dr_R_Kurzrock)

Results from the MOUNTAINEER trial show a clinically meaningful antitumor activity and favorable tolerability for tucatinib plus trastuzumab in metastatic colorectal cancer https://t.co/xjxSFJIir4 #fondazionebonadonna #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)

Excited to share the results of the MIMOSA-trial, in which we evaluated the novel combination of monalizumab & trastuzumab for HER2+ MBC! Thanks to the entire MIMOSA-team! @lab_kok https://t.co/WwufyrM0vG (@VeerleGeurts)

#WCGIC2023 💊 Emerging 🎯 in #GI cancer 🪑Dr. Van Cutsem + Dr. Carnero 🗣️@ValeGambardella 🎯 HER2 ✔️ T-DxT for #GastricCancer #DestinyGastric01 2nd line #FDA --> ⏳#DestinyGastric02 ✔️Trastuzumab + tucatinib for #CCR #MOUNTAINEER ✔️Zanidatamab #BiliaryTract #HERIZONBTC01 @WCGIC (@DrMirallas)

Yes definitely using in carcinosarcoma. What about advanced serous HER2 positive? Thoughts about IO vs trastuzumab? (@LAMcAlarnenMD)

34F, Rt multicenteric BCA, HER2 + TNBC. S/p ddAC+ T+H+P ->SM + SLN -> mpT1cN0. HER2 positive lesion not seen. How to select adjuvant Rx ? HERCEPTIN + capacitabine? @stolaney1 @IlanaSchlam @HemOncFellows @DFCI_BreastOnc (@Arif_Hameed)

Hot off the press from @ASCO #TAPUR Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/ilNcPYdV8U (@rschilsky)

Subcutaneous delivery of fixed-dose adjuvant pertuzumab + trastuzumab proved to have favorable tolerability, w/ a safety profile consistent with that seen with intravenous delivery of the regimen in pts w/ HER2+ breast cancer. @BCJoyceO #bcsm #oncology https://t.co/CmjDDZZyok (@OncLive)

Subcutaneous delivery of fixed-dose adjuvant pertuzumab + trastuzumab proved to have favorable tolerability, w/ a safety profile consistent with that seen with intravenous delivery of the regimen in pts w/ HER2+ breast cancer. @BCJoyceO #bcsm #oncology https://t.co/zuHJlfdCLv (@OncLive)

🆕HERIZON-BTC-01 study: Zanidatamab in previously-treated 🎯#HER2‑amplified biliary tract cancer (BTC) @DrShubhamPant Again gallbladder ca >1/2 of these cases. #ASCO23 @OncoAlert HER2➕in cholangiocarcinoma needs approvals. @NCCN only trastuzumab/pertuzumab. No @FDAOncology. (@pashtoonkasi)

Tucatinib plus trastuzumab for previously treated metastatic BTC with Her2 positive. Median PFS of 5.5 months. @ASCO @agrothey @GIcancerDoc #ASCO23 (@SuyogCancer)

🔥 SGNTUC-019: Tucatinib & trastuzumab for HER2+ biliary tract cancer #ASCO23 🔎phs-II, 30 pts, Her2 overexpression/amplification 👉ORR: 46.7%, DoR 6.0mo, DCR 76.7% 👉mPFS 5.5 mo, 12-mo OS rate 53.8% ✅Supports TUC/Tras as CTx-free💊option @myESMO @OncoAlert @EASLedu @curecc… https://t.co/s4WLttkRA2 (@ArndtVogel)

Enhertu made by @AstraZeneca who not yet involved in DETERMINE. There is an arm for HER2 mutated/ amplified using trastuzumab/pertuzumab. As Enhertu approved FDA should be evaluated by @MHRAgovuk and @NICEComms through project orbis. Need to ensure Her2 on test directory #lcsm (@AlastairGreyst2)

10/ 👀Two HER-2 targeted Tx trials for #cholangiocarcinoma 2 #ASCO23 this year ➡️Yoshiaki Nakamura et al, describe a 48% ORR with tucatinib + trastuzumab in BTC 🤔Was this is HER2 pre-treated patients❓ Abs4007 DOI: 10.1200/JCO.2023.41.16_suppl.4007 (@MPishvaian)

New 📰 | Impact of Neoadjuvant Paclitaxel/ Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ #BreastCancer. A Single-Arm Prospective Clinical Trial. @adawaksmd @DrAnnaWeiss @stolaney1 @AnnPartridgeMD @SChikarmaneMD Read it here⬇️ https://t.co/8Rn0UIdXQB (@DFCI_BreastOnc)

@ASCO TAPUR data coming soon in @JCOPO_ASCO on pertuzumab plus trastuzumab in NSCLC with ERBB2 exon 20 insertions! (@rschilsky)

Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Early Breast Cancer https://t.co/0iQYZcJzpZ via @JAMAOnc part of @JAMANetwork (@DrFaridSaleh)

Pertuzumab + trastuzumab @ASCO #TAPUR Study trial showing antitumor activity with a disease control rate of 37% in 28 evaluable patients w/ endometrial cancer w/ ERBB2/3 alterations 👉 https://t.co/2utDgpaXUm @eugeneahn @rschilsky et al (@JCOPO_ASCO)

Thank you Dr Dennis Slamon aka Mr Herceptin. #bcsm @myESMO Trastuzumab Has Changed the Natural History of Her2+ BC #ESMOBreast23 (@swaggsheila1)

👇🏾Here’s a personalized Share Link – a URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” 🙏🏽 @RueschCenter for 🔦 on our study. (@pashtoonkasi)

Tucatinib plus trastuzumab is a new treatment option for chemotherapy-refractory HER2-positive/RAS wild-type metastatic colorectal cancer-MOUNTAINEER https://t.co/GX61FjXMH7 (@drkpavithran)

Recently published in @JAMAOnc: Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Congrats @adawaksmd @stolaney1 @EMittendorfMD and colleagues! #breastcancer #bcsm (@DFCI_BreastOnc)

The terminology is confusing & in the above link we unpack causally what physician scientists mean by “prognostic” and “predictive”. Read the story of HER2 & trastuzumab in section 3.4. Breast cancer methodologists are most familiar with these nuances: https://t.co/J4OxdwWHSH (@PavlosMsaouel)

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/TWKHcuKxmh (@MLPOncoData)

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/OIScF6HZMS (@weldeiry)

Tucatinib+trastuzumab = new SOC for pts #HER2 + #colorectalcancer Success story of Academic-Industry Collab from IIT @accru__network --> promising results --> transfer IND to @SeagenGlobal with registration intent --> @FDAOncology approval in Jan 23 https://t.co/E18RrTfLp6 (@GIcancerDoc)

🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert https://t.co/lTXbE2bTTT (@ArndtVogel)

🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert (@ArndtVogel)

MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ mCRC is now published! 🔥 ORR: 38.1% (3 CRs) 🔥 Median OS > 2 years 👉 Diarrhea, LFT ⬆️, fatigue, skin rash are most common side effects (generally mild) 🚫 chemo in this regimen https://t.co/Ktyk14B1Bp (@SKamath_MD)

Exciting news! MOUNTAINEER shows an effective chemo-free targeted treatment option for HER2-positive mCRC. Tucatinib + trastuzumab adds a new weapon to the arsenal in our fight against #CRC. #HER2 @TheLancetOncol #precisionmedicine ⁦@OncoAlert⁩ https://t.co/ssykZkQ2tO (@SalemGIOncDoc)

"Exciting news! MOUNTAINEER shows an effective chemo-free targeted treatment option for HER2-amp mCRC.Tucatinib + trastuzumab adds a new weapon to the arsenal in our fight against #CRC.#HER2 ⁦@TheLancetOncol⁩ #precisionmedicine ⁦@OncoAlert⁩ https://t.co/ssykZkQ2tO (@SalemGIOncDoc)

👇🏾Here’s a personalized Share Link – a personalized URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” https://t.co/CKqGOLxdlw (@pashtoonkasi)

Our latest.. lead by @YJanjigianMD... Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study https://t.co/1a69lRbAnE (@LewisLabMSKCC)

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): … https://t.co/PuyvZ5PoNW Extenet...final installment? (@FilippoMontemu1)

Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC #crcsm @US_FDA @OSUCCC_James https://t.co/n1tc1sqOKE (@OncLive)

#AACR23 | Section 47 | Monday CT155 - Long Term Results and ctDNA Correlatives for CAPOX BETR: A Multi-center Phase II Trial of Capecitabine, Oxaliplatin, Bevacizumab and Trastuzumab for Previously Untreated HER2 Positive Metastatic Gastroesophageal Adenocarcinoma @KlempnerSam (@MGHCancerCenter)

Looking forward to sharing our work on spatial profiling of HER2+/HER2low #breastcancer. ➡️On the same day w Major Symposia on the past (25th Anniversary of Trastuzumab) & future (Mapping Spatial Technologies) of this work. Join us - post plenary, 10-11am Spotlight Theater Rm B (@StoverLab)

WATCH: @BCJoyceO discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer. #bcsm #oncology https://t.co/hfdOmnDvTb (@OncLive)

Just published! Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study https://t.co/GeWgWqTgV7 (@rschilsky)